Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Janux Therapeutics, Inc.JANX · Entity 4864 | Director | June 11, 2025 | June 13, 2025 |
| NKGen Biotech, Inc.NKGN · Entity 79017 | Director | September 29, 2023 | October 10, 2023 |
| eFFECTOR Therapeutics, Inc.EFTR · Entity 89916 | Chief Business Officer | June 20, 2022 | June 22, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Janux Therapeutics, Inc.
Report date June 11, 2025 · Filed June 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,250 |
Reported balance
After 2025-06-11 transaction · row 1
1 source rowRow 1 · 2025-06-11 · Grant · Acquired 3,750 · Balance 6,250 F1: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.46 · Expires 2035-06-10 | Direct | 11,667 |
Reported balance
After 2025-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-11 · Grant · Acquired 11,667 · Balance 11,667 F2: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.
F2: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.
NKGen Biotech, Inc.
Report date September 29, 2023 · Filed October 10, 2023
This filing explicitly reported no securities owned.
eFFECTOR Therapeutics, Inc.
Report date June 20, 2022 · Filed June 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.49 · Expires 2023-06-19 | Direct | 150,000 |
Reported balance
After 2022-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-20 · Grant · Acquired 150,000 · Balance 150,000 F1: The stock option vests 50% on June 20, 2023, and in 12 monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests 50% on June 20, 2023, and in 12 monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2025 Filed Jun 13, 2025 23:30 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 11,667 | $0.00 Strike: $25.46 | $0.00 |
DisclosureSEC source: 0001415889-25-017312 · form4-06132025_070605.xml · derivative · entry 2 McNulty Alana B. · CIK 0001606086 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,667 Underlying: Common Stock · 11,667 shares Expires 2035-06-10 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 23:30 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017312 · form4-06132025_070605.xml · nonDerivative · entry 1 McNulty Alana B. · CIK 0001606086 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,250 F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 20:30 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 8,350 | $0.00 Strike: $39.80 | $0.00 |
DisclosureSEC source: 0001415889-24-018442 · form4-06282024_040643.xml · derivative · entry 2 McNulty Alana B. · CIK 0001606086 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,350 Underlying: Common Stock · 8,350 shares Expires 2034-06-25 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 26, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date. Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 20:30 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-018442 · form4-06282024_040643.xml · nonDerivative · entry 1 McNulty Alana B. · CIK 0001606086 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 26, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:09 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001209191-23-037987 · doc4.xml · derivative · entry 1 McNulty Alana B. · CIK 0001606086 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-06-13 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2023, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders. Read SEC document |
| June 20, 2022 Filed Jun 22, 2022 16:19 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001209191-22-038679 · doc4.xml · derivative · entry 1 McNulty Alana B. · CIK 0001606086 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2023-06-19 F1 · derivative.exercise_date: The stock option vests 50% on June 20, 2023, and in 12 monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:36 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $10.73 | $0.00 |
DisclosureSEC source: 0001209191-22-037445 · doc4.xml · derivative · entry 1 McNulty Alana B. · CIK 0001606086 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2032-06-13 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2022, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders. Read SEC document |
| January 20, 2022 Filed Jan 24, 2022 20:10 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $6.65 | $0.00 |
DisclosureSEC source: 0001209191-22-004685 · doc4.xml · derivative · entry 1 McNulty Alana B. · CIK 0001606086 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2032-01-19 F1 · derivative.exercise_date: 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 20, 2022 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:36 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $29.58 | $0.00 |
DisclosureSEC source: 0001209191-21-055346 · doc4.xml · derivative · entry 1 McNulty Alana B. · CIK 0001606086 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-09-06 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over a three year period following September 7, 2021 (the "Grant Date") such that the option is fully vested on the third anniversary of the Grant Date. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 18:11 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | GrantEarn-out Right · Derivative | 91,826 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-053698 · doc4.xml · derivative · entry 9 McNulty Alana B. · CIK 0001606086 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,826 Underlying: Common Stock · 91,826 shares Expires not disclosed F10 · derivative.exercise_price: Each earn-out right represents a contingent right to receive one share of the Issuer's common stock. Pursuant to an "Earn-Out" provision in the Merger Agreement, the earn-out rights vest upon the Issuer's common stock achieving a price per share which equals or exceeds $20.00 over at least 20 trading days out of a 30 consecutive trading day period prior to August 26, 2023. F10 · shares: Each earn-out right represents a contingent right to receive one share of the Issuer's common stock. Pursuant to an "Earn-Out" provision in the Merger Agreement, the earn-out rights vest upon the Issuer's common stock achieving a price per share which equals or exceeds $20.00 over at least 20 trading days out of a 30 consecutive trading day period prior to August 26, 2023. F10 · price: Each earn-out right represents a contingent right to receive one share of the Issuer's common stock. Pursuant to an "Earn-Out" provision in the Merger Agreement, the earn-out rights vest upon the Issuer's common stock achieving a price per share which equals or exceeds $20.00 over at least 20 trading days out of a 30 consecutive trading day period prior to August 26, 2023. F10 · derivative.exercise_date: Each earn-out right represents a contingent right to receive one share of the Issuer's common stock. Pursuant to an "Earn-Out" provision in the Merger Agreement, the earn-out rights vest upon the Issuer's common stock achieving a price per share which equals or exceeds $20.00 over at least 20 trading days out of a 30 consecutive trading day period prior to August 26, 2023. F10 · derivative.expiration_date: Each earn-out right represents a contingent right to receive one share of the Issuer's common stock. Pursuant to an "Earn-Out" provision in the Merger Agreement, the earn-out rights vest upon the Issuer's common stock achieving a price per share which equals or exceeds $20.00 over at least 20 trading days out of a 30 consecutive trading day period prior to August 26, 2023. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 18:11 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | GrantStock Option (Right to Buy) · Derivative | 96,570 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001209191-21-053698 · doc4.xml · derivative · entry 8 McNulty Alana B. · CIK 0001606086 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,570 Underlying: Common Stock · 96,570 shares Expires 2030-04-12 F2 · shares: At the Effective Time, each outstanding option to purchase shares of old eFFECTOR common stock (each an "old eFFECTOR Option") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of old eFFECTOR common stock subject to the applicable old eFFECTOR Option multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole share. F9 · derivative.exercise_date: The stock option vests 25% on April 13, 2021, and in 36 monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 18:11 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | GrantStock Option (Right to Buy) · Derivative | 65,185 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001209191-21-053698 · doc4.xml · derivative · entry 7 McNulty Alana B. · CIK 0001606086 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,185 Underlying: Common Stock · 65,185 shares Expires 2029-06-05 F2 · shares: At the Effective Time, each outstanding option to purchase shares of old eFFECTOR common stock (each an "old eFFECTOR Option") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of old eFFECTOR common stock subject to the applicable old eFFECTOR Option multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole share. F8 · derivative.exercise_date: The stock option vests 25% on June 6, 2020, and in 36 monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 18:11 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | GrantStock Option (Right to Buy) · Derivative | 96,570 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001209191-21-053698 · doc4.xml · derivative · entry 6 McNulty Alana B. · CIK 0001606086 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,570 Underlying: Common Stock · 96,570 shares Expires 2027-08-20 F2 · shares: At the Effective Time, each outstanding option to purchase shares of old eFFECTOR common stock (each an "old eFFECTOR Option") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of old eFFECTOR common stock subject to the applicable old eFFECTOR Option multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole share. F7 · derivative.exercise_date: The stock option vests 25% on August 21, 2018, and in 36 monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 18:11 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | GrantStock Option (Right to Buy) · Derivative | 43,456 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001209191-21-053698 · doc4.xml · derivative · entry 5 McNulty Alana B. · CIK 0001606086 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,456 Underlying: Common Stock · 43,456 shares Expires 2026-02-16 F2 · shares: At the Effective Time, each outstanding option to purchase shares of old eFFECTOR common stock (each an "old eFFECTOR Option") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of old eFFECTOR common stock subject to the applicable old eFFECTOR Option multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole share. F6 · derivative.exercise_date: The stock option vests 25% on February 17, 2017, and in 36 monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 18:11 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | GrantStock Option (Right to Buy) · Derivative | 113,470 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001209191-21-053698 · doc4.xml · derivative · entry 4 McNulty Alana B. · CIK 0001606086 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,470 Underlying: Common Stock · 113,470 shares Expires 2026-01-07 F2 · shares: At the Effective Time, each outstanding option to purchase shares of old eFFECTOR common stock (each an "old eFFECTOR Option") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of old eFFECTOR common stock subject to the applicable old eFFECTOR Option multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole share. F5 · derivative.exercise_date: The stock option vests 25% on January 8, 2017, and in 36 monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 18:11 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | GrantStock Option (Right to Buy) · Derivative | 120,713 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001209191-21-053698 · doc4.xml · derivative · entry 3 McNulty Alana B. · CIK 0001606086 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,713 Underlying: Common Stock · 120,713 shares Expires 2025-10-18 F2 · shares: At the Effective Time, each outstanding option to purchase shares of old eFFECTOR common stock (each an "old eFFECTOR Option") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of old eFFECTOR common stock subject to the applicable old eFFECTOR Option multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole share. F4 · derivative.exercise_date: The stock option vests 25% on October 19, 2016, and in 36 monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 18:11 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | GrantStock Option (Right to Buy) · Derivative | 38,628 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001209191-21-053698 · doc4.xml · derivative · entry 2 McNulty Alana B. · CIK 0001606086 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,628 Underlying: Common Stock · 38,628 shares Expires 2024-12-03 F2 · shares: At the Effective Time, each outstanding option to purchase shares of old eFFECTOR common stock (each an "old eFFECTOR Option") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of old eFFECTOR common stock subject to the applicable old eFFECTOR Option multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole share. F3 · derivative.exercise_date: The stock option vests 25% on December 4, 2015, and in 36 monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 18:11 UTC | eFFECTOR Therapeutics, Inc. EFTR · Entity 89916 | GrantCommon Stock | 48,768 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-053698 · doc4.xml · nonDerivative · entry 1 McNulty Alana B. · CIK 0001606086 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,768 F1 · price: On August 25, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of May 26, 2021 (the "Merger Agreement"), by and among the Issuer (f/k/a Locust Walk Acquisition Corp.), Locust Walk Merger Sub, Inc. ("Merger Sub"), and eFFECTOR Therapeutics, Inc. ("Old eFFECTOR"), Merger Sub merged with and into Old eFFECTOR with Old eFFECTOR surviving as a wholly owned subsidiary of the Issuer (the "Merger"). Upon consummation of the Merger (the "Effective Time"), each issued and outstanding share of common stock of Old eFFECTOR was automatically cancelled and converted into approximately 0.09657 (the "Exchange Ratio") shares of common stock of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.